1. Cell Cycle/DNA Damage
    Epigenetics
  2. PARP

PARP

PARP is a family of proteins involved in a number of cellular processes involving mainly DNA repair and programmed cell death. The PARP family comprises 17 members. They have all very different structures and functions in the cell. PARP1, PARP2, VPARP (PARP4), Tankyrase-1 and -2 (PARP-5a or TNKS, and PARP-5b or TNKS2) have a confirmed PARP activity. Others include PARP3, PARP6, TIPARP (or PARP7), PARP8, PARP9, PARP10, PARP11, PARP12, PARP14, PARP15, and PARP16. PARP is found in the cell’s nucleus. The main role is to detect and signal single-strand DNA breaks (SSB) to the enzymatic machinery involved in the SSB repair.

PARP Related Products (29):

Cat. No. Product Name Effect Purity
  • HY-10162
    Olaparib Inhibitor 99.65%
    Olaparib is a potent PARP inhibitor with IC50 of 5 and 1 nM for PARP-1 and PARP-2, respectively.
  • HY-16106
    BMN-673 Inhibitor 99.78%
    BMN-673 is a novel PARP1/2 inhibitor with IC50 of 0.57 nM for PARP1.
  • HY-10619
    MK-4827 Inhibitor 99.39%
    MK-4827 is an excellent PARP1 and 2 inhibitor with IC50 of 3.8 and 2.1 nM, respectively.
  • HY-15147
    XAV-939 Inhibitor 98.04%
    XAV-939 is a selective Wnt pathway β-catenin-mediated transcription inhibitor and axin stabilizing agent with IC50 values of 11 and 4 nM for the inhibition of TNKS1 and TNKS2, respectively.
  • HY-10130
    Veliparib dihydrochloride Inhibitor 99.79%
    Veliparib (dihydrochloride) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively.
  • HY-19937A
    Saroglitazar (Magnesium) Agonist 98.85%
    Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
  • HY-18954
    NMS-P118 Inhibitor 99.08%
    NMS-P118 is a potent, orally available, and highly selective PARP-1 Inhibitor for cancer therapy.
  • HY-100828
    BGP-15 Inhibitor >98.0%
    BGP-15 is a PARP inhibitor, that can protect against heart failure and atrial fibrillation in mice.
  • HY-10617
    Rucaparib phosphate Inhibitor 99.56%
    Rucaparib (phosphate) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, and also shows binding affinity to eight other PARP domains.
  • HY-13688
    PJ34 hydrochloride Inhibitor 98.44%
    PJ34 hydrochloride is a potent specific inhibitor of PARPl/2 with IC50 of 110 nM and 86 nM, respectively.
  • HY-B0150
    Nicotinamide Inhibitor 99.94%
    Nicotinamide is a water-soluble vitamin, an active component of coenzymes NAD and NADP, and acts as poly (ADP-ribose) polymerase (PARP) inhibitor.
  • HY-10619B
    MK-4827 tosylate Inhibitor 98.96%
    MK-4827 tosylate is an excellent PARP1 and 2 inhibitor with IC50 of 3.8 and 2.1 nM, respectively.
  • HY-13990
    NVP-TNKS656 Inhibitor
    NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM, and is > 300 fold selectivity against PARP1 and PARP2.
  • HY-10614
    A-966492 Inhibitor 99.31%
    A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively.
  • HY-10129
    Veliparib Inhibitor >98.0%
    Veliparib is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with Kis of 5.2 and 2.9 nM, respectively.
  • HY-13536
    AZD-2461 Inhibitor 98.12%
    AZD2461 is a novel PARP inhibitor, which has the potential to avoid the olaparib resistence mediated by Pgp.
  • HY-12418
    E7449 Inhibitor 98.72%
    E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2; enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors.
  • HY-12438
    G007-LK Inhibitor 98.29%
    G007-LK displays high selectivity toward tankyrases 1 and 2 with biochemical IC50 values of 46 nM and 25 nM, respectively, and a cellular IC50 value of 50 nM combined with an excellent pharmacokinetic profile in mice.
  • HY-12015
    BSI-201 Inhibitor
    BSI-201 (Iniparib; NSC-746045) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC).
  • HY-12022
    INO-1001 Inhibitor 99.69%
    INO-1001 is a potent inhibitor of PARP with IC50 of < 50 nM in CHO cells, and acts as a mediator of oxidant-induced myocyte dysfunction during reperfusion.